– ISRAEL, Migdal HaEmek – Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced that its Board of Directors has appointed Erez Israeli as President and Chief Executive Officer effective April 18, 2017. Mr. Israeli succeeds Dr. Ariel Katz, who has served as Enzymotec’s President and Chief Executive Officer since 2001.
“I am excited and pleased to welcome Erez to the Enzymotec team as President and Chief Executive Officer. We believe that Erez’s years of experience, strategic vison and leadership capabilities will support a seamless leadership transition,” commented Steve Dubin, Enzymotec’s Chairman of the Board. “Erez has developed transformational strategies at Teva Pharmaceuticals to generate commercial growth in complex multi-national organizations and has helped drive the efficiency and effectiveness of sales and marketing teams. Those capabilities will serve Erez and Enzymotec well as we seek to strategically grow our core businesses and position the Company for long-term success. I would also like to thank Dr. Ariel Katz for his many years of leadership and innovative vision at Enzymotec. His work has helped lay the foundation for a robust business from which we can build.”
Mr. Israeli has more than 20 years of experience in strategic planning, business processes, operation, quality, finance and global sales and marketing. Mr. Israeli was most recently the President and CEO of Growth Markets at Teva Pharmaceuticals where he oversaw all commercial activities in Asia, Asia Pacific, Africa and Latin America. Since joining Teva in 1994, he has held various leadership roles including the Head of Global Quality, President and CEO of Teva API and President, and Group Executive Vice President and Chief Business Process Officer at Teva. Mr. Israeli obtained his MBA in Finance and Marketing from Bar Ilan University, Israel.
Erez Israeli added, “I am excited to take the helm at Enzymotec, and I hope to continue building on the strong foundation that Ariel has laid by bringing a renewed vision to drive growth and success in the company’s range of businesses. I look forward to leveraging my deep experience in global markets to drive the expansion of the company’s growth opportunities to become a strong international player.”
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
For more information : http://www.enzymotec.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.